Sector movers: Defensives pace gains
25th Nov 2016 16:42
(ShareCast News) - Defensive issues and so-called 'bond proxies' performed best at the tail-end of the week, with shares of personal goods and health care equipment companies pacing gains. Among the former of those two sectors, it was Unilever which did best after the manufacturer said it would appe
Read moreBroker tips: AstraZeneca, Daily Mail, Domino's
25th Nov 2016 15:23
(ShareCast News) - Liberum upgraded AstraZeneca to 'buy' from 'hold'. The brokerage had harboured concerns about the risks to the company's global Phase 3 study of durvalumab, MYSTIC, earnings weakness and bid speculation unwinding. However, with the stock down around 20% and at low not seen since
Read moreLiberum upgrades AstraZeneca to 'buy' from 'hold'
25th Nov 2016 08:37
(ShareCast News) - Liberum upgraded AstraZeneca to 'buy' from 'hold'. The brokerage had harboured concerns about the risks to the company's global Phase 3 study of durvalumab, MYSTIC, earnings weakness and bid speculation unwinding. However, with the stock down around 20% and at lows not seen since
Read moreLondon close: Miners propel FTSE 100 higher as industrial metals surge
22nd Nov 2016 16:34
(ShareCast News) - London equities ended Tuesday on a sharply higher note with major miners storming ahead in tandem with soaring industrial metals prices, and followed by a string of banks and insurers. US interest rate-touch utilities were firmly higher, too. FTSE 100 closed the session up 0.62%
Read moreAstraZeneca resumes enrolment for new cancer drug trial
22nd Nov 2016 07:45
(ShareCast News) - AstraZeneca said on Tuesday that it will resume enrolment for a new cancer drug trial of durvalumab after the US Food and Drug Administration lifted a partial clinical hold on the enrolment of new patients with head and neck cancer. The pharmaceutical company said the Phase III Ke
Read moreThursday broker round-up
17th Nov 2016 13:00
(ShareCast News) - Kingfisher: HSBC reiterates hold with a target price of 380p. Astrazeneca: Berenberg reiterates buy with a 55p target. Aggreko: Jefferies stays at hold with a 750p target. Easyjet: Barclays reiterates equal-weight rating with a 1000p target. Amec Foster Wheeler: UBS keeps at ne
Read moreAstraZeneca completes licensing deal with Allergan
17th Nov 2016 07:20
(ShareCast News) - AstraZeneca announced the completion of the licensing agreement between MedImmune, its global biologics research and development arm, and Allergan, for the global rights to MEDI2070 on Thursday. The FTSE 100 firm said MEDI2070 is an IL-23 monoclonal antibody currently in a Phase I
Read moreTuesday broker round-up
15th Nov 2016 12:30
(ShareCast News) - Dairy Crest: Jefferies downgrades to underperform with a target price of 500p. Royal Dutch Shell: HSBC reiterates buy with a 2360p target. Polymetal: Jefferies stays at underperform with a 700p target. Tesco: Credit Suisse reiterates underperform with a 130p target. Paddy Power
Read moreLondon close: Blue chips slide, led by gold-exposed miners amid profit-taking
10th Nov 2016 17:01
(ShareCast News) - London blue-chip stocks fell on Thursday as traders took profits stoked by Donald Trump's election win, with gold-exposed miners, pharmaceutical and US rates-sensitive utilities all flopping. The FTSE 100 ended the session down 1.21% to 6,827.98 points, somewhat out of kilter with
Read moreAstrazeneca reports worse-than-expected drop in Q3 revenue
10th Nov 2016 08:41
(ShareCast News) - Astrazeneca shares edged lower on Thursday as it reported a worse-than-expected drop in third quarter revenue. Revenue fell 4% to $5.7bn in the three months ended 30 September, missing forecasts of $5.87bn, as cheaper generic versions of its best-selling medicine Crestor hurt sale
Read moreAnalysts pick winners as pharma sector bounces back on Clinton loss
9th Nov 2016 13:58
(ShareCast News) - The pharmaceuticals sector bounced back after Donald Trump won the battle to become the next president of the United States and the Republican party won control of Congress, with analysts suggesting AstraZeneca, Shire and Eli Lilly were among the best placed stocks to capitalise o
Read moreThursday preview: Astrazeneca to report decline in third quarter sales
9th Nov 2016 12:31
(ShareCast News) - Astrazeneca is expected to report a drop in third quarter sales on Thursday after failing to prevent generic drug makers from bringing cheaper rivals of its best-selling medicine Crestor. Analysts expect generic versions of cholesterol fighting drug Crestor will have sent revenue
Read moreFriday broker round-up
28th Oct 2016 15:33
(ShareCast News) - Barclays: JP Morgan keeps at neutral with a target price of 190p. Standard Life: Jefferies stays at buy, 391p target. Senior: Berenberg reiterates buy with a 220p target. Imperial Brands: Deutsche Bank reiterates buy with a 4600p target. ITV: Credit Suisse reiterates outperform
Read moreAstraZeneca reports positive results for ovarian cancer trial
26th Oct 2016 07:04
(ShareCast News) - Pharmaceutical giant AstraZeneca reported that its Lynparza drug had positive results from a clinical trial to treat women with mutated ovarian cancer. In a phase-three trial Lynparza tablets were used as a monotherapy to treat platinum-sensitive replaced BRCA-mutated ovarian canc
Read moreFDA accepts review of AstraZeneca drug for hyperkalaemia
18th Oct 2016 07:21
(ShareCast News) - The US Food and Drug Administration has accepted a complete re-submission of a new drug application for sodium zirconium cyclosilicate (ZS-9), a potential new medicine for the treatment of hyperkalaemia by AstraZeneca's subsidiary ZS Pharma. Hyperkalaemia - high potassium levels i
Read more